- The CDC reports over 2.8 million antimicrobial-resistant infections occur annually in the U.S., with global deaths at 1.27 million.
- FendX Technologies (FDXTF, Financial) is developing surface protection products, including the REPELWRAP™ film, to combat antimicrobial resistance (AR).
- FendX signs a letter of intent with US BioSolutions for eco-friendly microbe-trapping technology.
FendX Technologies Inc. (FDXTF), a company at the forefront of developing surface protection products, has highlighted recent reports from the Centers for Disease Control and Prevention (CDC) regarding the escalating threat of antimicrobial resistance (AR). The CDC's February 2025 report indicates that the United States experiences over 2.8 million antimicrobial-resistant infections each year, with at least 1.27 million deaths occurring globally due to these infections. The cost of treating six common AR infections in healthcare settings in the U.S. is estimated to exceed US$4.6 billion annually.
One of the notable concerns from the CDC report is the five-fold increase in cases of Candida auris, a drug-resistant yeast, between 2019 and 2022. This yeast has seen recent surges in New York, Georgia, and Florida and has been classified by the CDC as an "urgent threat" due to its resistance to treatment.
In response to these alarming statistics, FendX is actively developing innovative surface protection solutions. Their flagship product, the REPELWRAP™ film, is currently undergoing real-world testing to verify its effectiveness in repelling pathogens. Additionally, FendX is working on early-stage development of a spray and catheter coating to further mitigate the spread of AR pathogens.
Expanding their technological portfolio, FendX has signed a letter of intent with US BioSolutions to acquire intellectual property and establish a supply agreement for a revolutionary eco-friendly sponge designed to attract and trap microbes when used with a cleaning agent. Dr. Carolyn Myers, CEO and President of FendX, emphasized the importance of their products in controlling the spread of infections, especially in hospital settings where recent outbreaks have occurred.
The company's ongoing commitment to addressing the global challenge of AR through cutting-edge nanotechnology positions it as a crucial player in the healthcare industry’s battle against these resistant strains. For more information on FendX Technologies and their projects, visit their website at [FendX Technologies](https://fendxtech.com/).
